Free Trial

iRhythm Technologies Q4 2022 Earnings Report

iRhythm Technologies logo
$90.39 +2.73 (+3.11%)
(As of 12/20/2024 05:16 PM ET)

iRhythm Technologies EPS Results

Actual EPS
-$0.67
Consensus EPS
-$0.63
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

iRhythm Technologies Revenue Results

Actual Revenue
$112.62 million
Expected Revenue
$110.62 million
Beat/Miss
Beat by +$2.00 million
YoY Revenue Growth
N/A

iRhythm Technologies Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

First JFK… next Elon? (Ad)

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

iRhythm Technologies Earnings Headlines

iRhythm price target raised to $111 from $85 at Truist
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
J.P. Morgan Remains a Buy on Irhythm Technologies (IRTC)
iRhythm price target raised to $152 from $125 at Canaccord
iRhythm resumed with an Equal Weight at Wells Fargo
See More iRhythm Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iRhythm Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iRhythm Technologies and other key companies, straight to your email.

About iRhythm Technologies

iRhythm Technologies (NASDAQ:IRTC), a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

View iRhythm Technologies Profile

More Earnings Resources from MarketBeat

Upcoming Earnings